| Year |
Citation |
Score |
| 2012 |
Thompson VB, Koprich JB, Chen EY, Kordower JH, Terpstra BT, Lipton JW. Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicology and Teratology. 34: 206-13. PMID 21978916 DOI: 10.1016/J.Ntt.2011.09.005 |
0.649 |
|
| 2010 |
Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 16091-101. PMID 21123556 DOI: 10.1523/Jneurosci.2400-10.2010 |
0.364 |
|
| 2009 |
Chung CY, Koprich JB, Hallett PJ, Isacson O. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proceedings of the National Academy of Sciences of the United States of America. 106: 22474-9. PMID 20007772 DOI: 10.1073/Pnas.0912193106 |
0.358 |
|
| 2009 |
Emborg ME, Moirano J, Raschke J, Bondarenko V, Zufferey R, Peng S, Ebert AD, Joers V, Roitberg B, Holden JE, Koprich J, Lipton J, Kordower JH, Aebischer P. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiology of Disease. 36: 303-11. PMID 19660547 DOI: 10.1016/J.Nbd.2009.07.022 |
0.582 |
|
| 2009 |
Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 3365-73. PMID 19295143 DOI: 10.1523/Jneurosci.5427-08.2009 |
0.363 |
|
| 2007 |
Chung CY, Koprich JB, Endo S, Isacson O. An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 8314-23. PMID 17670978 DOI: 10.1523/Jneurosci.1972-07.2007 |
0.319 |
|
| 2007 |
He B, Counts SE, Perez SE, Hohmann JG, Koprich JB, Lipton JW, Steiner RA, Crawley JN, Mufson EJ. Corrigendum to "ectopic galanin expression and normal galanin receptor 2 and galanin receptor 3 mRNA levels in the forebrain of galanin transgenic mice" [Neuroscience 133 (2005) 371-380] (DOI:10.1016/j.neuroscience.2005.01.068) Neuroscience. 144: 1544. DOI: 10.1016/J.Neuroscience.2006.12.005 |
0.6 |
|
| 2006 |
Campbell NG, Koprich JB, Kanaan NM, Lipton JW. MDMA administration to pregnant Sprague-Dawley rats results in its passage to the fetal compartment. Neurotoxicology and Teratology. 28: 459-65. PMID 16905291 DOI: 10.1016/J.Ntt.2006.05.006 |
0.618 |
|
| 2005 |
Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, Sisodia SS, Mufson EJ. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 10220-9. PMID 16267229 DOI: 10.1523/Jneurosci.2773-05.2005 |
0.583 |
|
| 2005 |
He B, Counts SE, Perez SE, Hohmann JG, Koprich JB, Lipton JW, Steiner RA, Crawley JN, Mufson EJ. Ectopic galanin expression and normal galanin receptor 2 and galanin receptor 3 mRNA levels in the forebrain of galanin transgenic mice. Neuroscience. 133: 371-80. PMID 15885921 DOI: 10.1016/J.Neuroscience.2005.01.068 |
0.609 |
|
| 2003 |
Koprich JB, Campbell NG, Lipton JW. Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. Brain Research. Developmental Brain Research. 147: 177-82. PMID 14741762 DOI: 10.1016/S0165-3806(03)00219-0 |
0.662 |
|
| 2003 |
Lipton JW, Gyawali S, Borys ED, Koprich JB, Ptaszny M, McGuire SO. Prenatal cocaine administration increases glutathione and alpha-tocopherol oxidation in fetal rat brain. Brain Research. Developmental Brain Research. 147: 77-84. PMID 14741753 DOI: 10.1016/J.Devbrainres.2003.08.006 |
0.594 |
|
| 2003 |
Koprich JB, Chen EY, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicology and Teratology. 25: 509-17. PMID 12972064 DOI: 10.1016/S0892-0362(03)00091-6 |
0.653 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2011 |
Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Plos One. 6: e17698. PMID 21408191 DOI: 10.1371/Journal.Pone.0017698 |
0.298 |
|
| 2006 |
Emborg ME, Roitberg BZ, Moirano J, Zufferey R, Ebert AD, Joers V, Holden J, Converse AK, Koprich JB, Kordower JH, Aebischer P. Lentiviral Delivery of Glial Cell Line-derived Neurotrophic Factor in Aged 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Rhesus Monkeys 883. Neurosurgery. 59: 481-482. PMID 28180727 DOI: 10.1227/00006123-200608000-00121 |
0.263 |
|
| 2019 |
Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease. Scientific Reports. 9: 8362. PMID 31182727 DOI: 10.1038/s41598-019-42847-x |
0.251 |
|
| 2010 |
Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Molecular Neurodegeneration. 5: 43. PMID 21029459 DOI: 10.1186/1750-1326-5-43 |
0.251 |
|
| 2019 |
Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB. Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. PMID 30918068 DOI: 10.1124/jpet.118.255695 |
0.245 |
|
| 2017 |
Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Acta Neuropathologica Communications. 5: 11. PMID 28143577 DOI: 10.1186/S40478-017-0416-X |
0.233 |
|
| 2008 |
Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. Journal of Neuroinflammation. 5: 8. PMID 18304357 DOI: 10.1186/1742-2094-5-8 |
0.226 |
|
| 2022 |
Musacchio T, Yin J, Kremer F, Koprich JB, Brotchie JM, Volkmann J, Ip CW. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease. Behavioural Brain Research. 432: 113968. PMID 35738338 DOI: 10.1016/j.bbr.2022.113968 |
0.225 |
|
| 2021 |
Bu LL, Liu YQ, Shen Y, Fan Y, Yu WB, Jiang DL, Tang YL, Yang YJ, Wu P, Zuo CT, Koprich JB, Liu FT, Wu JJ, Wang J. Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33723752 DOI: 10.1007/s13311-021-01018-5 |
0.216 |
|
| 2017 |
Arathoon LR, Gleave JA, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism. Neurobiology of Disease. PMID 28673739 DOI: 10.1016/J.Nbd.2017.06.009 |
0.203 |
|
| 2020 |
Shen Y, Yu WB, Shen B, Dong H, Zhao J, Tang YL, Fan Y, Yang YF, Sun YM, Luo SS, Chen C, Liu FT, Wu JJ, Xiao BG, Yu H, ... Koprich JB, et al. Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice. Brain : a Journal of Neurology. PMID 33170925 DOI: 10.1093/brain/awaa283 |
0.196 |
|
| 2023 |
McFleder RL, Makhotkina A, Groh J, Keber U, Imdahl F, Peña Mosca J, Peteranderl A, Wu J, Tabuchi S, Hoffmann J, Karl AK, Pagenstecher A, Vogel J, Beilhack A, Koprich JB, et al. Brain-to-gut trafficking of alpha-synuclein by CD11c cells in a mouse model of Parkinson's disease. Nature Communications. 14: 7529. PMID 37981650 DOI: 10.1038/s41467-023-43224-z |
0.196 |
|
| 2020 |
McKinnon C, De Snoo ML, Gondard E, Neudorfer C, Chau H, Ngana SG, O'Hara DM, Brotchie JM, Koprich JB, Lozano AM, Kalia LV, Kalia SK. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathologica Communications. 8: 17. PMID 32059750 DOI: 10.1186/s40478-020-0894-0 |
0.195 |
|
| 2016 |
Koprich JB, Johnston TH, Reyes G, Omana V, Brotchie JM. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. Plos One. 11: e0167235. PMID 27902767 DOI: 10.1371/journal.pone.0167235 |
0.193 |
|
| 2016 |
Ip CW, Isaias IU, Kusche-Tekin BB, Klein D, Groh J, O'Leary A, Knorr S, Higuchi T, Koprich JB, Brotchie JM, Toyka KV, Reif A, Volkmann J. Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury. Acta Neuropathologica Communications. 4: 108. PMID 27716431 DOI: 10.1186/S40478-016-0375-7 |
0.192 |
|
| 2015 |
He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. Molecular Neurobiology. PMID 25972237 DOI: 10.1007/s12035-015-9173-7 |
0.189 |
|
| 2018 |
Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146]. Neurobiology of Disease. PMID 29571591 DOI: 10.1016/J.Nbd.2018.02.018 |
0.184 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of Aging. 33: 207.e9-19. PMID 21051107 DOI: 10.1016/J.Neurobiolaging.2010.09.011 |
0.173 |
|
| 2022 |
Matschke LA, Komadowski MA, Stöhr A, Lee B, Henrich MT, Griesbach M, Rinné S, Geibl FF, Chiu WH, Koprich JB, Brotchie JM, Kiper AK, Dolga AM, Oertel WH, Decher N. Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease. Scientific Reports. 12: 3180. PMID 35210472 DOI: 10.1038/s41598-022-06832-1 |
0.172 |
|
| 2017 |
Matschke L, Henrich M, Stoehr A, Chiu W, Lee B, Geibl F, Koprich J, Decher N, Oertel WH. Targeted overexpression of A53T-alpha-synuclein induces progressive neurodegeneration and electrophysiological changes of noradrenergic locus coeruleus neurons – A preclinical model of Parkinson's disease Basal Ganglia. 8: 6. DOI: 10.1016/J.Baga.2017.02.017 |
0.167 |
|
| 2018 |
Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. Acta Neuropathologica Communications. 6: 39. PMID 29747690 DOI: 10.1186/S40478-018-0541-1 |
0.163 |
|
| 2013 |
Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 43: 151-6. PMID 23306217 DOI: 10.1016/J.Pnpbp.2012.12.008 |
0.162 |
|
| 2004 |
Krenitsky TA, Dillberger J, Zotova E, Arezzo JC, Koprich JB, Mortazavi F, Gates TA, Dunbar GL. KP544, a nerve growth factor amplifier: Pharmacokinetics, safety, and efficacy in the rat Drug Development Research. 62: 60-70. DOI: 10.1002/Ddr.10384 |
0.162 |
|
| 2017 |
Koprich JB, Brotchie JM, Musacchio T, Volkmann J, Ip CW. Reply to Can STN DBS protect both nigral somata and innervation of the striatum? Annals of Neurology. PMID 28985651 DOI: 10.1002/Ana.25066 |
0.155 |
|
| 2011 |
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7190-8. PMID 21562283 DOI: 10.1523/Jneurosci.1171-11.2011 |
0.154 |
|
| 2013 |
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacological Reviews. 65: 171-222. PMID 23319549 DOI: 10.1124/Pr.111.005678 |
0.151 |
|
| 2023 |
Grotemeyer A, Fischer JF, Koprich JB, Brotchie JM, Blum R, Volkmann J, Ip CW. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease. Journal of Neuroinflammation. 20: 79. PMID 36945016 DOI: 10.1186/s12974-023-02759-0 |
0.148 |
|
| 2023 |
Taymans JM, Mutez E, Sibran W, Vandewynckel L, Deldycke C, Bleuse S, Marchand A, Sarchione A, Leghay C, Kreisler A, Simonin C, Koprich J, Baille G, Defebvre L, Dujardin K, et al. Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson's disease and pharmacodynamic biomarkers. Npj Parkinson's Disease. 9: 21. PMID 36750568 DOI: 10.1038/s41531-023-00445-9 |
0.146 |
|
| 2012 |
Huot P, Koprich J, Johnston T, Fox S, Brotchie J. 2.217 PHARMACOKINETIC PROFILE OF THE SELECTIVE DOPAMINE D4 RECEPTOR ANTAGONIST L-745,870 IN THE MPTP-LESIONED NON-HUMAN PRIMATE MODEL OF PARKINSON'S DISEASE Parkinsonism & Related Disorders. 18: S119. DOI: 10.1016/S1353-8020(11)70541-7 |
0.146 |
|
| 2013 |
Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology. 73: 337-47. PMID 23770260 DOI: 10.1016/J.Neuropharm.2013.06.005 |
0.141 |
|
| 2009 |
Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM. New insights into the organization of the basal ganglia. Current Neurology and Neuroscience Reports. 9: 298-304. PMID 19515282 DOI: 10.1007/S11910-009-0045-2 |
0.139 |
|
| 2014 |
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. 82: 76-87. PMID 24447715 DOI: 10.1016/J.Neuropharm.2014.01.012 |
0.136 |
|
| 2019 |
Karikari AA, Koprich JB, Ip CW. Generation and Analysis of Viral Vector-Mediated Rodent Models for Parkinson's Disease. Methods in Molecular Biology (Clifton, N.J.). 1948: 271-286. PMID 30771185 DOI: 10.1007/978-1-4939-9124-2_21 |
0.131 |
|
| 2015 |
Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behavioural Pharmacology. 26: 101-8. PMID 25303957 DOI: 10.1097/Fbp.0000000000000096 |
0.128 |
|
| 2017 |
Musacchio T, Rebenstorff M, Fluri F, Brotchie JM, Volkmann J, Koprich JB, Ip CW. STN-DBS is neuroprotective in the A53T α-synuclein Parkinson's disease rat model. Annals of Neurology. PMID 28470693 DOI: 10.1002/Ana.24947 |
0.127 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 342: 576-85. PMID 22619253 DOI: 10.1124/Jpet.112.195693 |
0.127 |
|
| 2020 |
Wang S, Kelly K, Brotchie JM, Koprich JB, West AB. Exosome markers of LRRK2 kinase inhibition. Npj Parkinson's Disease. 6: 32. PMID 33298972 DOI: 10.1038/s41531-020-00138-7 |
0.123 |
|
| 2021 |
Chiu WH, Kovacheva L, Musgrove RE, Arien-Zakay H, Koprich JB, Brotchie JM, Yaka R, Ben-Zvi D, Hanani M, Roeper J, Goldberg JA. α-Synuclein-induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms. Science Advances. 7. PMID 33692101 DOI: 10.1126/sciadv.abd3994 |
0.121 |
|
| 2011 |
Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1225-33. PMID 21465551 DOI: 10.1002/mds.23631 |
0.113 |
|
| 2016 |
Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends in Neurosciences. PMID 27776749 DOI: 10.1016/J.Tins.2016.09.003 |
0.113 |
|
| 2012 |
Koprich J, Johnston T, Huot P, Brotchie J. 3.118 PRIMATE AND RODENT MODELS OF PARKINSON'S DISEASE BASED ON VIRAL VECTOR MEDIATED OVEREXPRESSION OF ALPHA SYNUCLEIN Parkinsonism & Related Disorders. 18: S193. DOI: 10.1016/S1353-8020(11)70834-3 |
0.111 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology. 63: 829-36. PMID 22722022 DOI: 10.1016/J.Neuropharm.2012.06.012 |
0.109 |
|
| 2022 |
Karikari AA, McFleder RL, Ribechini E, Blum R, Bruttel V, Knorr S, Gehmeyr M, Volkmann J, Brotchie JM, Ahsan F, Haack B, Monoranu CM, Keber U, Yeghiazaryan R, Pagenstecher A, ... ... Koprich JB, et al. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice. Brain, Behavior, and Immunity. PMID 35032575 DOI: 10.1016/j.bbi.2022.01.007 |
0.104 |
|
| 2018 |
Schuman B, Won A, Brand-Arzamendi K, Koprich JB, Wen XY, Howson PA, Brotchie JM, Yip CM. Non-steric-zipper models for pathogenic α-synuclein conformers. Apl Bioengineering. 2: 026105. PMID 31069302 DOI: 10.1063/1.5023460 |
0.1 |
|
| 2009 |
Johnston T, Koprich J, Fox S, Howson P, Brotchie J. P2.201 PYM50028 (Cogane™) is a small molecule inducer of GDNF and BDNF that reverses behavioural impairment in MPTP-lesioned macaques Parkinsonism & Related Disorders. 15: S144. DOI: 10.1016/S1353-8020(09)70552-8 |
0.098 |
|
| 2017 |
Liu ZY, Liu FT, Zuo CT, Koprich JB, Wang J. Update on Molecular Imaging in Parkinson's Disease. Neuroscience Bulletin. PMID 29282614 DOI: 10.1007/s12264-017-0202-6 |
0.091 |
|
| 2015 |
Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM. Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1283-8. PMID 26377152 DOI: 10.1002/Mds.26302 |
0.09 |
|
| 2017 |
Koprich JB, Kalia LV, Brotchie JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nature Reviews. Neuroscience. PMID 28747776 DOI: 10.1038/nrn.2017.75 |
0.088 |
|
| 2013 |
Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque. The European Journal of Neuroscience. 37: 831-8. PMID 23281915 DOI: 10.1111/Ejn.12093 |
0.086 |
|
| 2020 |
Titze-de-Almeida SS, Soto-Sánchez C, Fernandez E, Koprich JB, Brotchie JM, Titze-de-Almeida R. The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. Cells. 9. PMID 32244357 DOI: 10.3390/cells9040841 |
0.085 |
|
| 2012 |
Johnston T, Koprich J, Fox S, Meyers N, Ward C, Hickling R, Howson P, Brotchie J. 2.230 PYM50028, AN ORALLY ACTIVE NEUROTROPHIC FACTOR MODULATOR, ENHANCES THE EFFECT OF L-DOPA AND REDUCES L-DOPA-INDUCED DYSKINESIA IN MPTP-LESIONED MACAQUES Parkinsonism & Related Disorders. 18: S122. DOI: 10.1016/S1353-8020(11)70554-5 |
0.079 |
|
| 2022 |
Badr M, McFleder RL, Wu J, Knorr S, Koprich JB, Hünig T, Brotchie JM, Volkmann J, Lutz MB, Ip CW. Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice. Journal of Neuroinflammation. 19: 319. PMID 36587195 DOI: 10.1186/s12974-022-02685-7 |
0.076 |
|
| 2018 |
Koprich J, Johnston T, Howson P, Reyes G, Omana V, Brotchie J. Characterization and reproducibility of a macaque model of Parkinson’s disease alpha-synucleinopathy Parkinsonism & Related Disorders. 46: e3-e4. DOI: 10.1016/j.parkreldis.2017.11.012 |
0.074 |
|
| Hide low-probability matches. |